 | |
| Clinical data | |
|---|---|
| Trade names | Bafiertam |
| License data | |
| Routes of administration | By mouth |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.018.557 |
| Chemical and physical data | |
| Formula | C5H6O4 |
| Molar mass | 130.099 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Monomethyl fumarate, sold under the brand nameBafiertam is amedication used for the treatment of relapsing forms ofmultiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.[1] It is takenby mouth.[1]
The most common adverse reactions areflushing,abdominal pain,diarrhea, andnausea.[1]
It was approved for medical use in the United States in April 2020.[2][3]
Monomethyl fumarate alters theNFE2L2 (Nuclear factor erythroid 2-related factor 2) transcription factor.
NFE2L2 (or NRF2) is a basic leucine zipper (bZIP) protein that regulates the expression of antioxidant proteins that protect against oxidative damage triggered by injury and inflammation. Several drugs that stimulate the NFE2L2 pathway are being studied for treatment of diseases that are caused byoxidative stress.
Two precursors are also approved:
Monomethyl fumarate is theinternational nonproprietary name (INN).[11]
